Drug Trial Radar · NCT05734521
Avalglucosidase Alfa Pregnancy Study
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 26, 2022
Primary completion
Oct 31, 2032
Study completion Oct 31, 2032
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a worldwide, descriptive safety study collecting data on women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation, to assess the risks of avalglucsodiase alfa on pregnancy and maternal complications and adverse effects in the developing fetus, neonate, and infant. * Outcomes in exposed infants, including growth and development, will be assessed through at least the first year of life. * Data will be collected for approximately 10 years.
Conditions
- Pompe Disease
- Pregnancy
Interventions
avalglucosidase alfa-NGPT (GZ402666) IVBiological
intravenous infusion
avalglucosidase alfa-NGPT (GZ402666)Biological
exposed via pregnancy and lactation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maternal complicationsTime frame: through study completion, an average of 10 years
- Pregnancy outcomeTime frame: through study completion, an average of 10 years
- Infant outcomeTime frame: through study completion, an average of 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site worldwide
Bridgewater, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.